ANI Pharmaceuticals Competitors and Similar CompaniesClear all
ANI Pharmaceuticals's competitors and similar companies include Sorrento Therapeutics, scPharmaceuticals, Merus and Olainfarm.
 ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  scPharmaceuticals scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. |  Olainfarm Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia. | |
Founding Date | Founding Date 1996 | Founding Date 2006 | Founding Date 2014 | Founding Date 2003 | Founding Date 1972 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Baudette, US HQ Oakville, CA Baudette, US | Locations San Diego, US HQ San Diego, US | Locations Burlington, US HQ | Locations Utrecht, NL HQ Cambridge, US | Locations Olaine, LV HQ |
Employees | Employees 33813% increase | Employees 31019% decrease | Employees 96256% increase | Employees 172 | Employees 2,191 |
Valuation ($) | Valuation ($) 1.2 b | Valuation ($) 1.5 m | Valuation ($) 221.6 m | Valuation ($) 3.6 b | Valuation ($) 150.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $614.4m (FY, 2024) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $13.6m (FY, 2023) | Revenue (est.) $43.9m (FY, 2023) | Revenue (est.) €122.2m (FY, 2020) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $3.8m (FY, 2023) | Cost of goods N/A | Cost of goods €44.5m (FY, 2020) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $43.9m (FY, 2023) | Gross profit €80.1m (FY, 2020) |
Net income | Net income ($18.5m) (FY, 2024) | Net income ($577.8m) (FY, 2022) | Net income ($54.8m) (FY, 2023) | Net income ($154.9m) (FY, 2023) | Net income €9.5m (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 62.5m | Total funding raised $ 149.3m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyscPharmaceuticals
HQ
Burlington, US
Employees
96
scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.
View companyMerus
HQ
Utrecht, NL
Employees
172
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View companyOlainfarm
HQ
Olaine, LV
Employees
2,191
Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia.
View company